{
    "clinical_study": {
        "@rank": "120898", 
        "arm_group": {
            "arm_group_label": "HM781-36B(Poziotinib), Paclitaxel, Trastuzumab", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "[Phase I] The main objective of this study is to evaluate the safety, tolerability and\n      determine the Recommended Dose (RD) of HM781-36B(Poziotinib)combined with Paclitaxel and\n      Trastuzumab\n\n      [Phase II] The main objective of this study is to evaluate anticancer activity through\n      determination of response rate of HM781-36B(Poziotinib)combined with Paclitaxel and\n      Trastuzumab in patients with HER-2 positive advanced gastric cancer"
        }, 
        "brief_title": "A Phase I-II Study of HM781-36B(Poziotinib)Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "HER-2 Positive Advanced Gastric Cancer", 
        "condition_browse": {
            "mesh_term": "Stomach Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Besides the main objectives, there are other objectives as follows:\n\n      [Phase I]\n\n        1. To assess the pharmacokinetic profile of HM781-36B(Poziotinib) combined with Paclitaxel\n           and Trastuzumab\n\n        2. To evaluate anticancer activity of HM781-36B(Poziotinib) combined with Paclitaxel and\n           Trastuzumab in patients with HER-2 positive advanced gastric cancer\n\n        3. To evaluate PFS(Progression-Free Survival), TTP (Time To Tumor Progression), and DOR\n           (Duration of Overall Response)\n\n      [Phase II]\n\n        1. To assess the safety, tolerability of HM781-36B(Poziotinib) combined with Paclitaxel\n           and Trastuzumab\n\n        2. To evaluate tumor response through determination of disease control rate ,\n           PFS(Progression-Free Survival), TTP (Time To Tumor Progression), and DOR (Duration of\n           Overall Response)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Histologically or cytologically confirmed advanced gastric cancer  including\n             gastroesophageal junction adenocarcinoma\n\n          2. At least one measurable lesion defined by RECIST(v1.1)\n\n          3. FISH+ or IHC3+ (regardless of FISH results)\n\n          4. Age\u226519\n\n          5. ECOG \u2264 2\n\n          6. Life expectancy \u2265 12 weeks\n\n          7. Adequate bone marrow and no abnormal heart and lung function\n\n          8. No radiotherapy, other anticancer drugs or immunotherapy is allowed during this study\n\n          9. Subjects must provide written informed consent prior to performance of study specific\n             procedures or assessments, and must be willing to comply with treatment and follow up\n             assessments and procedures\n\n        Exclusion Criteria:\n\n          1. Patients with a hitory of hypersensitivity to Trastuzumab and who have been treated\n             with medicine including Cremophor EL\n\n          2. Patients who have a current active malignancy other than gastric adenocarcinoma (with\n             exception of non-melanoma skin cancer or cervical cancer in situ)\n\n          3. Patients who have previously received taxane-based chemotherapy\n\n          4. The presence of central nervous system metastases\n\n          5. Patients who have a blood tumor such as leukemia, or who had previously received, or\n             are planning to receive, the bone marrow transplant\n\n          6. Patients with uncontrolled infection\n\n          7. Patients who have GI malabsorption or difficulty taking oral medication\n\n          8. Patients with following diseases are excluded:\n\n          9. Patients with psychiatric or congenital disorder which can affect adherence or make\n             hard to follow the requirements of the protocol\n\n         10. Pregnant or breastfeeding women or women of childbearing who do not use an\n             appropriate method of contraception (male patient should also use an appropriate\n             method of contraception)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01746771", 
            "org_study_id": "HM-PHI-A201"
        }, 
        "intervention": [
            {
                "arm_group_label": "HM781-36B(Poziotinib), Paclitaxel, Trastuzumab", 
                "intervention_name": "HM781-36B(Poziotinib)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "NOV120101", 
                    "Poziotinib"
                ]
            }, 
            {
                "arm_group_label": "HM781-36B(Poziotinib), Paclitaxel, Trastuzumab", 
                "intervention_name": "Paclitaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "HM781-36B(Poziotinib), Paclitaxel, Trastuzumab", 
                "intervention_name": "Trastuzumab", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Paclitaxel", 
                "Trastuzumab"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "HM781-36B, Paclitaxel, Trastuzumab", 
        "lastchanged_date": "June 20, 2013", 
        "location": {
            "contact": {
                "email": "bangyj@snu.ac.kr", 
                "last_name": "Yung-Jue Bang"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Seoul National University Hospital"
            }, 
            "investigator": {
                "last_name": "Yung-Jue Bang", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I-II Study to Assess the Safety, Efficacy and Pharmacokinetic Profile of HM781-36B Combined With Paclitaxel and Trastuzumab in Patients With HER-2 Positive Advanced Gastric Cancer", 
        "overall_contact": {
            "email": "kmpark@hanmi.co.kr", 
            "last_name": "Kyung-Mi Park"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Dose limiting toxicity (DLT), Maximum tolerance dose (MTD)", 
            "measure": "Safety evaluation(phase I)", 
            "safety_issue": "Yes", 
            "time_frame": "DLT will be evaluated on Day 21 during cycle 1"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01746771"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Efficacy evaluation; phase II (Simon's two-stage minimax design): Disease Control Rate (CR, PR, SD), PFS(Progression-Free Survival), TTP (Time To Tumor Progression), and DOR (Duration of Overall Response)", 
            "measure": "Efficacy evaluation(Phase II)", 
            "safety_issue": "No", 
            "time_frame": "Efficacy will be evaluated every 6 weeks or 9 weeks"
        }, 
        "source": "Hanmi Pharmaceutical Company Limited", 
        "sponsors": {
            "collaborator": {
                "agency": "National OncoVenture", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Hanmi Pharmaceutical Company Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}